Jaime Rabi, director of Microbiológica, documents the unique development path of the company and its pioneering contribution to the production of antiretroviral medicines in Brazil, as well as its international partnerships with American success-stories like Pharmasset, which originally developed the breakthrough therapy sofosbuvir. He also provides insights into the remarkable collaborative approach favored by the company, be it regarding API or finished product development, as well as its longstanding commitment to enriching the Brazilian R&D ecosystem.
Microbiológica displays one of the most eye-catching histories in Brazil’s healthcare and life sciences industry. Could you walk us through the company’s main milestones?
“Working in technology had quickly made me realize that my scientific vocation could find challenging objectives in industry too.”
